immuno-oncology

Immuno-oncology agents continue to transform cancer treatment landscape:  GlobalData

Read more

Advanced antibodies will revolutionise the future of Immuno-Oncology (IO)

Read more

Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData

Read more

Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData

Read more

Zydus Cadila inks licensing pact with XOMA Corp

Read more

Sanofi teams up with Evotec, Apeiron

Read more